Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 125

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 125
---
----------|:----|:-----------------|-------:|:--|:----|:-----|-------:|:--|
|                                           |     | USD in thousands |        |   |     |      |        |   |
| Net cash used in operating activities     |     |                  | (4,859 | ) |     |      | (6,301 | ) |
| Net cash used in investing activities     |     |                  |   (238 | ) |     |      |    (26 | ) |
| Net cash provided by financing activities |     |                  |  6,254 |   |     |      | 11,664 |   |
| Effect of foreign exchange on cash        |     |                  |    (11 | ) |     |      |    (38 | ) |
| Net increase in cash                      |     |                  |  1,146 |   |     |      |  5,299 |   |

77 Net cash used in operating activities Net cash used in operating activities for the year ended October 31, 2024, amounted to $ 4,858,659 representing an increase of $1,442,813, or 22.9%, compared to $6,301,472 for the year ended October 31, 2023. This decrease was mainly due to decrease in the net loss. Net cash used in investing activities Net cash used in investing activities for the year ended October 31, 2024, amounted to $238,097 representing an increase of $211,869 or 807.8%, compared to $26,228 for the year ended October 31, 2023. This increase was mainly due to acquisition of short-term investments. Net cash provided by financing activities Net cash provided by financing activities for the year ended October 31, 2024, amounted to $ 6,254,378 representing a decrease of $5,410,018, or 46.4%, compared to $11,664,396 for the year ended October 31, 2023. This decrease was due to fewer financing transactions in the current period when compared to the financing transactions in the prior period. We have incurred losses and cash flow deficits from operations since inception, resulting in an accumulated deficit as of October 31, 2024 of $24,022,741 and as of July 31, 2025 of $27,191,882. We anticipate that we will continue to incur net losses for